Company news
Gan & Lee Pharmaceuticals Co., Ltd. Class A (SSE:603087) news
Gan & Lee Pharmaceuticals Co., Ltd. Class A news releases on 6ix. Latest, Sep 19, 2026: "Gan & Lee Pharmaceuticals"Announcement on Obtaining Notice…
Press releases & updates
"Gan & Lee Pharmaceuticals"Announcement on Obtaining Notice of Approval for Drug Clinical Trials
September 18, 2026
"Gan & Lee Pharmaceuticals"Announcement on Completion of Industrial and Commercial Registration Information Change
September 8, 2026
"Gan & Lee Pharmaceuticals"Announcement on Completion of First Subject Dosing in the Phase I Clinical Trial of GZC8072 Tablets
September 7, 2026
"Gan & Lee Pharmaceuticals"Announcement on Obtaining Notice of Approval for Drug Clinical Trial for the New Indication of GZC8072 Tablet
September 3, 2026
"Gan & Lee Pharmaceuticals."Announcement on Release of Pledge of Certain Shares Held by Shareholder Holding More Than 5% of the Shares
August 26, 2026
"Gan & Lee Pharmaceuticals."Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026
August 25, 2026
"Gan & Lee Pharmaceuticals."Announcement on Obtaining Notice of Approval for Drug Clinical Trials
August 24, 2026
"Gan & Lee Pharmaceuticals"Announcement on the Listing and Trading of Certain Restricted Shares from the Initial Public Offering
August 18, 2026
"Gan & Lee Pharmaceuticals"Announcement on Signing of the Authorization and License Agreement for the Bofanglutide Project with Menarini Group
August 10, 2026
"Gan & Lee Pharmaceuticals"Announcement on Implementation of Repurchase and Cancellation of Certain Restricted Shares under the 2022 and 2024 Restricted Share Incentive Plans
August 7, 2026
"Gan & Lee Pharmaceuticals."Announcement on Shareholding Reduction Plan by Directors and Senior Management
August 6, 2026
"Gan & Lee Pharmaceuticals."Announcement on Completion of Registration of the Grant under the 2026 Restricted Share Incentive Plan
July 28, 2026
"Gan & Lee Pharmaceuticals"Review Opinion of the Remuneration and Appraisal Committee of the Board of Directors on Matters Relating to the Grant of Restricted Shares to the Participants under the Company's 2026 Restricted Share Incentive Plan
July 15, 2026
"Gan & Lee Pharmaceuticals"Announcement on Obtaining Notice of Approval for Drug Clinical Trial
July 10, 2026
"Gan & Lee Pharmaceuticals"Announcement on the Grant of the Drug Registration Approval for Insulin Glargine Injection (Prefilled Pen) in Honduras
July 9, 2026
Announcement on Obtaining Drug Registration Approval from Honduras for Insulin Glargine Injection
June 26, 2026
Verification Opinions of Remuneration and Appraisal Committee of Board of Directors on List of Incentive Objects and Publicity Results in 2026 Restricted Stock Incentive Plan
June 22, 2026
Announcement on Obtaining the Drug Registration Approval in the United Arab Emirates for Insulin Glargine Injection (Pre-filled Pen)
June 18, 2026
Gan & Lee Pharmaceuticals Achieves Significant Progress in Its Dual Pipeline for Metabolic Diseases -- Weekly Insulin Ludefen (GZR4) Meets Primary Endpoint in Phase III Clinical Trial in China; Bofanglutide Meets Primary Endpoints in Phase III Weight Loss Study in China and Phase II Study in the U.S.
June 12, 2026
Indicative Announcement on Unlocking of the 3rd Sales Restriction Lifting Period under the 2022 Restricted Stock Incentive Plan and Unlocking and Listing of the 2nd Sales Restriction Lifting Period under the 2024 Restricted Stock Incentive Plan
June 11, 2026
Notice on Convening the 1st Extraordinary General Meeting in 2026
June 10, 2026
Announcement on Release of Pledge of Partial Shares Held by Shareholders with Over 5% Shares
June 2, 2026
Announcement on Sterile Preparations Passing ANVISA GMP Certification
May 26, 2026
Announcement on Implementation of Dividend Distribution for 2025
May 24, 2026
Announcement on Obtaining of European Commission Marketing Authorization for Insulin Lispro Injection
May 14, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 13, 2026
Announcement on Obtaining of European Commission Marketing Authorization for Aspart Injection
May 6, 2026
Announcement on Completion of Administration of the First Subject in Phase III Clinical Trial of New Indication of Bofanglutide (GZR18) Injection
April 23, 2026
Notice on Convening the 2025 Annual General Meeting
April 22, 2026
Announcement on Obtaining Notice of Approval for Drug Clinical Trial
April 21, 2026
Announcement on Completion of Administration of the First Subject in Phase III Clinical Trial of GZR33 Injection
April 14, 2026
Gan & Lee Pharmaceuticals Signs Exclusive License Agreement with JW Pharmaceutical, the Leading South Korean Pharma, to Advance the Global Commercialization of the Innovative GLP-1 Receptor Agonist Bofanglutide
April 9, 2026
Announcement on Obtaining Drug Registration Approval by Wholly-owned Subsidiary
April 7, 2026
Announcement on Completion of Administration of the First Subject in Phase I Clinical Trial of GLR2037 Tablets
April 3, 2026
Announcement on the Company Passing ANVISA GMP Certification
April 2, 2026
Gan & Lee Pharmaceuticals' Once-Weekly Basal Insulin GZR4 Injection Meets Primary Endpoints in Two Pivotal Phase 3 Clinical Trials: SUPER-1 and SUPER-2
March 31, 2026
Announcement on Obtaining the Clinical Trial Approval Notification for the New Indication of Bofang Glutide (Development Code: GZR18) Injection
March 24, 2026
Announcement on Appointment of Senior Management Members
March 6, 2026
Announcement on Positive Opinion from the European Medicines Agency's CHMP on the Marketing Authorization Application for Insulin Lispro Injection (Bysumlog®) and Insulin Aspart Injection (Dazparda®)
February 26, 2026
Announcement on Change of Sponsor Representative
February 24, 2026
Announcement on Expected Increase in Performance for 2025
January 21, 2026
Announcement on Obtaining the Ethiopian Drug Registration Approval for Insulin Glargine Injection and Its Pre-filled Injection Pen
January 15, 2026
Announcement on Obtaining of European Commission Marketing Authorization for Insulin Glargine Injection
January 14, 2026
Announcement on Progress in Redemption of Idle Raised Funds Used for Cash Management upon Expiration and Continuously Conducting Cash Management
January 13, 2026
Announcement on the Dismissal of Senior Management Member and Designation of Designated Personnel to Assume the Duties of the Financial Director
December 31, 2025
Once-Monthly GLP-1 RA | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management
November 27, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
November 17, 2025
Announcement on Positive CHMP Opinion Received for Marketing Authorization Application (MAA) of Insulin Glargine Injection (Ondibta?)
November 13, 2025
Announcement on Resolutions of the 5th Meeting of the 5th Board of Directors
November 10, 2025
Announcement on Canceling Board of Supervisors, Amending the "Articles of Association", Handling Industrial and Commercial Change Registration, and Revising Some Governance Systems
October 30, 2025